EE04579B1 - Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks - Google Patents

Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks

Info

Publication number
EE04579B1
EE04579B1 EEP200000770A EEP200000770A EE04579B1 EE 04579 B1 EE04579 B1 EE 04579B1 EE P200000770 A EEP200000770 A EE P200000770A EE P200000770 A EEP200000770 A EE P200000770A EE 04579 B1 EE04579 B1 EE 04579B1
Authority
EE
Estonia
Prior art keywords
arthropathies
preparation
treatment
pharmaceutical composition
protein transferase
Prior art date
Application number
EEP200000770A
Other languages
English (en)
Inventor
Pierre Frans Van Wauwe Jean
William End David
Lucie Louise Cools Marina
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200000770A publication Critical patent/EE200000770A/et
Publication of EE04579B1 publication Critical patent/EE04579B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EEP200000770A 1998-07-06 1999-06-30 Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks EE04579B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202258 1998-07-06
PCT/EP1999/004546 WO2000001386A1 (en) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors for treating arthropathies

Publications (2)

Publication Number Publication Date
EE200000770A EE200000770A (et) 2002-04-15
EE04579B1 true EE04579B1 (et) 2006-02-15

Family

ID=8233891

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000770A EE04579B1 (et) 1998-07-06 1999-06-30 Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks

Country Status (34)

Country Link
US (1) US6451812B1 (et)
EP (1) EP1094815B1 (et)
JP (1) JP4491136B2 (et)
KR (1) KR100674122B1 (et)
CN (1) CN1170538C (et)
AP (1) AP1597A (et)
AT (1) ATE253914T1 (et)
AU (1) AU762470B2 (et)
BG (1) BG64939B1 (et)
BR (1) BR9911869A (et)
CA (1) CA2337800C (et)
CZ (1) CZ302269B6 (et)
DE (1) DE69912790T2 (et)
DK (1) DK1094815T3 (et)
EA (1) EA003510B1 (et)
EE (1) EE04579B1 (et)
ES (1) ES2212580T3 (et)
HK (1) HK1034450A1 (et)
HR (1) HRP20000904A2 (et)
HU (1) HU229358B1 (et)
ID (1) ID27199A (et)
IL (2) IL140720A0 (et)
MY (1) MY122189A (et)
NO (1) NO318338B1 (et)
NZ (1) NZ509647A (et)
PL (1) PL193296B1 (et)
PT (1) PT1094815E (et)
SI (1) SI1094815T1 (et)
SK (1) SK285231B6 (et)
TR (1) TR200003882T2 (et)
TW (1) TW557212B (et)
UA (1) UA64797C2 (et)
WO (1) WO2000001386A1 (et)
ZA (1) ZA200100152B (et)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337800C (en) 1998-07-06 2007-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
PT1106612E (pt) * 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024683A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
ES2313991T3 (es) 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
ATE321038T1 (de) 2000-09-25 2006-04-15 Janssen Pharmaceutica Nv Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
AU2001293835A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
ES2328225T3 (es) 2000-11-21 2009-11-11 Janssen Pharmaceutica Nv Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
ATE325116T1 (de) * 2000-12-27 2006-06-15 Janssen Pharmaceutica Nv Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate
WO2002051835A1 (en) 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
WO2003000705A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
WO2003051880A1 (en) 2001-12-19 2003-06-26 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
EP1490065B1 (en) 2002-03-22 2007-06-13 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
AU2003229688B2 (en) 2002-04-15 2009-07-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1815247B1 (en) 2004-11-05 2013-02-20 Janssen Pharmaceutica NV Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US7826982B2 (en) 2005-07-29 2010-11-02 Children's Hospital Medical Center Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
EP2064243A2 (en) 2006-08-28 2009-06-03 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
JP5456658B2 (ja) 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
AU2008256928A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
CA2743717A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
FR2967353B1 (fr) * 2010-11-16 2013-08-16 Centre Nat Rech Scient Derives de quinolinone
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
NZ706775A (en) * 2012-10-16 2018-10-26 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
CA2888480C (en) * 2012-10-16 2021-03-16 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of ror.gamma.t
SG11201502935VA (en) * 2012-10-16 2015-09-29 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
SG11201509982UA (et) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
RU2699289C2 (ru) 2013-08-26 2019-09-04 Байонтек Рисерч Энд Дивелопмент, Инк. НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
JP6377152B2 (ja) * 2013-10-15 2018-08-22 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのフェニル結合キノリニルモジュレータ
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
EP3057421B1 (en) 2013-10-15 2019-11-20 Janssen Pharmaceutica NV Alkyl linked quinolinyl modulators of ror(gamma)t
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PT3154583T (pt) 2014-06-04 2021-03-24 Biontech Res And Development Inc Anticorpos monoclonais humanos para o gangliósido gd2
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
EP3229838B1 (en) 2014-12-11 2020-09-09 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
WO2016139482A1 (en) 2015-03-03 2016-09-09 Kymab Limited Antibodies, uses & methods
DK3277842T5 (da) 2015-08-17 2020-08-31 Kura Oncology Inc Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
AU2016365318B2 (en) 2015-12-02 2024-04-18 Board Of Regents, The University Of Texas System Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
US11124839B2 (en) 2016-11-03 2021-09-21 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3630834A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
FR2729390A1 (fr) * 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
CA2231105C (en) 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
JP2000508661A (ja) 1996-04-15 2000-07-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 放射線および化学療法に対する細胞の感作
AU709409B2 (en) * 1996-07-15 1999-08-26 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
GB2323783A (en) * 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
AU738628B2 (en) 1997-04-25 2001-09-20 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
CA2290992C (en) * 1997-06-02 2008-02-12 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
IL133449A0 (en) 1997-06-17 2001-04-30 Schering Corp Benzo (5, 6) cyclohepta (1, 2-b) pyridine derivatives as farnesyl protein transferase inhibitors
CA2337800C (en) 1998-07-06 2007-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
TR200003879T2 (tr) 1998-07-06 2007-01-22 Janssen Pharmaceutica N.V. İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
JP3495706B2 (ja) * 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体
JP5574025B1 (ja) * 2013-06-25 2014-08-20 大日本印刷株式会社 飲料供給系配管の殺菌方法及び装置

Also Published As

Publication number Publication date
ES2212580T3 (es) 2004-07-16
IL140720A0 (en) 2002-02-10
CN1308535A (zh) 2001-08-15
HUP0103670A2 (hu) 2002-02-28
PT1094815E (pt) 2004-04-30
WO2000001386A1 (en) 2000-01-13
AP1597A (en) 2006-04-26
TR200003882T2 (tr) 2001-06-21
HU229358B1 (en) 2013-11-28
EP1094815B1 (en) 2003-11-12
CA2337800A1 (en) 2000-01-13
MY122189A (en) 2006-03-31
BG64939B1 (bg) 2006-10-31
DE69912790D1 (de) 2003-12-18
AU4780699A (en) 2000-01-24
CN1170538C (zh) 2004-10-13
EP1094815A1 (en) 2001-05-02
EA200100112A1 (ru) 2001-06-25
AP2001002058A0 (en) 2001-03-31
BR9911869A (pt) 2001-03-27
EA003510B1 (ru) 2003-06-26
KR100674122B1 (ko) 2007-01-26
NO20010053D0 (no) 2001-01-04
CZ302269B6 (cs) 2011-01-19
IL140720A (en) 2008-08-07
NO20010053L (no) 2001-03-02
SI1094815T1 (en) 2004-04-30
ATE253914T1 (de) 2003-11-15
TW557212B (en) 2003-10-11
DE69912790T2 (de) 2004-09-23
KR20010052771A (ko) 2001-06-25
BG105110A (en) 2001-11-30
JP4491136B2 (ja) 2010-06-30
AU762470B2 (en) 2003-06-26
DK1094815T3 (da) 2004-03-29
SK19872000A3 (sk) 2001-08-06
NO318338B1 (no) 2005-03-07
EE200000770A (et) 2002-04-15
US6451812B1 (en) 2002-09-17
HRP20000904A2 (en) 2001-12-31
UA64797C2 (uk) 2004-03-15
PL345352A1 (en) 2001-12-17
ZA200100152B (en) 2002-01-07
HUP0103670A3 (en) 2003-01-28
CZ20004778A3 (en) 2001-05-16
HK1034450A1 (en) 2001-10-26
ID27199A (id) 2001-03-08
SK285231B6 (sk) 2006-09-07
JP2002519379A (ja) 2002-07-02
NZ509647A (en) 2003-12-19
CA2337800C (en) 2007-12-04
PL193296B1 (pl) 2007-01-31

Similar Documents

Publication Publication Date Title
EE200000770A (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
EE04582B1 (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis
DK1204410T3 (da) Farmaceutisk doseringsform med flere komponenter
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
DE60038698D1 (de) Hydrogel-gesteuerte dosierungsform
DE69928777D1 (de) Dosierspender
NO20003219L (no) Oral farmasøytisk doseringsform med pulsert frigivningsvirkning
NO20003218D0 (no) Oralfarmasøytisk doseringsform med forlenget frigivningsvirkning
NO20053106D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse.
NL300328I2 (nl) Samenstelling orale dosering met verlengde afgifte
NO20021329L (no) Kinaseinhibitorer som terapeutiske midler
DK1600154T3 (da) Osmotisk doseringsform med forlænget frigivelse
DE69704965D1 (de) Dosierungs-Ausgabebehälter
NO20010556L (no) Fremgangsmate for oftalmisk administrering
NO992692L (no) Nefadozon doseringsform
HUP0203054A3 (en) Farnesyl protein transferase inhibitors, pharmaceutical compositions containing them and their use
NO20012976D0 (no) Anvendelse av inhibitorer av KQTI-kanalen for fremstilling av et medikament
NO20002526L (no) Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav
NO20002439D0 (no) Nye orale doseringsformer for carvediol
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
EE9400296A (et) Piperidinüültioindooli derivaadid, ravimvormid, aktiivne valuvaigisti, nende valmistamise meetodid
ID30032A (id) Formulasi farmasi
DE10081194D2 (de) Darreichungsform zur Applikation in Körperöffnungen
EE200100281A (et) Analgeetiline ravimkoostis

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231